A detailed history of Geode Capital Management, LLC transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 508,827 shares of CUE stock, worth $534,268. This represents 0.0% of its overall portfolio holdings.

Number of Shares
508,827
Previous 492,456 3.32%
Holding current value
$534,268
Previous $610,000 36.72%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.45 - $1.08 $7,366 - $17,680
16,371 Added 3.32%
508,827 $386,000
Q2 2024

Aug 09, 2024

SELL
$1.24 - $2.18 $429,133 - $754,443
-346,075 Reduced 41.27%
492,456 $610,000
Q1 2024

May 13, 2024

BUY
$1.77 - $3.09 $44,685 - $78,010
25,246 Added 3.1%
838,531 $1.58 Million
Q4 2023

Feb 13, 2024

BUY
$1.72 - $3.1 $87,486 - $157,678
50,864 Added 6.67%
813,285 $2.15 Million
Q3 2023

Nov 13, 2023

BUY
$2.23 - $4.69 $73,536 - $154,657
32,976 Added 4.52%
762,421 $1.75 Million
Q2 2023

Aug 11, 2023

BUY
$3.11 - $4.91 $860,465 - $1.36 Million
276,677 Added 61.11%
729,445 $2.66 Million
Q1 2023

May 15, 2023

BUY
$2.41 - $3.74 $330,027 - $512,159
136,941 Added 43.36%
452,768 $1.62 Million
Q4 2022

Feb 13, 2023

BUY
$2.39 - $3.95 $41,158 - $68,022
17,221 Added 5.77%
315,827 $900,000
Q3 2022

Nov 14, 2022

BUY
$2.23 - $3.37 $1,190 - $1,799
534 Added 0.18%
298,606 $665,000
Q2 2022

Aug 12, 2022

SELL
$2.49 - $5.92 $623,329 - $1.48 Million
-250,333 Reduced 45.65%
298,072 $742,000
Q1 2022

May 13, 2022

BUY
$4.41 - $12.28 $119,074 - $331,572
27,001 Added 5.18%
548,405 $2.68 Million
Q4 2021

Feb 11, 2022

SELL
$10.86 - $17.85 $879,746 - $1.45 Million
-81,008 Reduced 13.45%
521,404 $5.9 Million
Q3 2021

Nov 12, 2021

BUY
$10.06 - $15.3 $866,095 - $1.32 Million
86,093 Added 16.67%
602,412 $8.78 Million
Q2 2021

Aug 13, 2021

BUY
$10.9 - $14.53 $329,943 - $439,823
30,270 Added 6.23%
516,319 $6.02 Million
Q1 2021

May 12, 2021

BUY
$11.2 - $16.09 $620,323 - $891,160
55,386 Added 12.86%
486,049 $5.93 Million
Q4 2020

Feb 12, 2021

BUY
$11.12 - $16.4 $434,302 - $640,518
39,056 Added 9.97%
430,663 $5.39 Million
Q3 2020

Nov 13, 2020

BUY
$15.05 - $23.54 $216,253 - $338,246
14,369 Added 3.81%
391,607 $5.89 Million
Q2 2020

Aug 13, 2020

BUY
$12.7 - $30.73 $871,867 - $2.11 Million
68,651 Added 22.25%
377,238 $9.25 Million
Q1 2020

May 14, 2020

BUY
$9.85 - $22.27 $447,002 - $1.01 Million
45,381 Added 17.24%
308,587 $4.38 Million
Q4 2019

Feb 13, 2020

BUY
$7.06 - $17.47 $370,452 - $916,685
52,472 Added 24.9%
263,206 $4.18 Million
Q3 2019

Nov 12, 2019

BUY
$6.78 - $9.28 $38,008 - $52,023
5,606 Added 2.73%
210,734 $1.78 Million
Q2 2019

Aug 14, 2019

BUY
$7.18 - $9.65 $423,210 - $568,799
58,943 Added 40.32%
205,128 $1.84 Million
Q1 2019

May 14, 2019

BUY
$4.7 - $9.29 $71,552 - $141,430
15,224 Added 11.62%
146,185 $1.13 Million
Q4 2018

Feb 13, 2019

BUY
$4.35 - $8.73 $64,915 - $130,277
14,923 Added 12.86%
130,961 $615,000
Q3 2018

Nov 13, 2018

BUY
$7.91 - $11.89 $50,014 - $75,180
6,323 Added 5.76%
116,038 $1.05 Million
Q2 2018

Aug 14, 2018

BUY
$10.93 - $14.48 $420,597 - $557,204
38,481 Added 54.02%
109,715 $1.3 Million
Q1 2018

May 15, 2018

BUY
$11.63 - $17.25 $828,451 - $1.23 Million
71,234 New
71,234 $1 Million

Others Institutions Holding CUE

About Cue Biopharma, Inc.


  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $37.2M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.